Clinical Trial Update: Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A multicenter Phase 2 trial sponsored by PharmaMar for relapsed/refractory aggressive non-Hodgkin lymphoma has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Yondelis (trabectedin)

Snippet

Sponsor: PharmaMar | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-03-29